Urovant Drug Patent Portfolio
Urovant owns 1 orange book drug protected by 4 US patents Given below is the list of Urovant's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12102638 | Use of vibegron to treat overactive bladder | 22 Mar, 2040 | Active |
| US12180219 | Process for preparing beta 3 agonists and intermediates | 12 Mar, 2034 | Active |
| US8247415 | Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists | 01 Dec, 2030 | Active |
| US8653260 | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | 02 Apr, 2029 | Active |
Latest Legal Activities on Urovant's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Urovant.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US8653260 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US8247415 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 05 Feb, 2024 | US8247415 |
| Second letter to regulating agency to determine regulatory review period | 06 Feb, 2023 | US8653260 |
| Second letter to regulating agency to determine regulatory review period | 06 Feb, 2023 | US8247415 |
| Letter from FDA or Dept of Agriculture re PTE application | 18 Jan, 2023 | US8653260 |
| Letter from FDA or Dept of Agriculture re PTE application | 18 Jan, 2023 | US8247415 |
| Initial letter Re: PTE Application to regulating agency | 30 Nov, 2021 | US8653260 |
| Initial letter Re: PTE Application to regulating agency | 30 Nov, 2021 | US8247415 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Jul, 2021 | US8653260 |
| Post Issue Communication - Certificate of Correction | 25 Feb, 2021 | US8653260 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 24 Feb, 2021 | US8653260 |
|
Email Notification
Critical
| 24 Feb, 2021 | US8653260 |
|
Correspondence Address Change
Critical
| 19 Feb, 2021 | US8653260 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Feb, 2020 | US8247415 |
Urovant's Family Patents
Urovant drugs have patent protection in a total of 40 countries. It's US patent count contributes only to 14.8% of its total global patent coverage. 10 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Urovant Drug List
Given below is the complete list of Urovant's drugs and the patents protecting them.
1. Gemtesa
Gemtesa is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12102638 | Use of vibegron to treat overactive bladder |
22 Mar, 2040
(14 years from now)
| Active |
| US12180219 | Process for preparing beta 3 agonists and intermediates |
12 Mar, 2034
(8 years from now)
| Active |
| US8247415 | Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists |
01 Dec, 2030
(5 years from now)
| Active |
| US8653260 | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists |
02 Apr, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gemtesa's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List